


Cell Reports, Volume 42

Supplemental information

**Reprogramming of tumor-associated macrophages
via NEDD4-mediated CSF1R degradation
by targeting USP18**

Sayuri Miyauchi, Kei-ichiro Arimoto, Mengdan Liu, Yue Zhang, and Dong-Er Zhang

A



B




Figure S1, Related to Figure 1. Normal hematopoiesis in *Usp18*^{Δ/Δ} mice

(A) Hematological analysis of peripheral blood from *Usp18*^{fl/fl} *LysM-Cre*^{-/-} (n = 12), *Usp18*^{fl/fl} *LysM-Cre*^{+/-} (n = 17) or *Usp18*^{fl/fl} *LysM-Cre*^{+/+} mice (n = 8). Mean ± S.D. WBC; white blood cells, RBC; red blood cells, PLT; platelets, LYM; lymphocytes, MON; monocytes, GRA; granulocytes.

(B) The total bone marrow cells were harvested from *Usp18*^{fl/fl} *UBC-Cre-ERT2* mice and the deletion of *Usp18* was induced by β-estradiol treatment *in vitro*. After 48 hours, the cell viability of CD11b⁺ myeloid cells was analyzed by flow cytometry (n = 3). Mean ± S.E.M.




Figure S2, Related to Figure 3. Single-cell analysis of tumor-infiltrating immune cells

(A) Feature plots of intratumoral CD45⁺ cells from merged sample.

(B) UMAP plot of intratumoral CD45⁺ cells split by *Usp18*^{fl/fl} and *Usp18*^{Δ/Δ} mice.

(C) A representative cell type and supporting marker gene heatmap generated by the automated annotation program SingleR.

(D) Feature plots of monocytes/macrophages/dendritic cells/neutrophils subpopulation (Mono/Mac/DC/Neu).

(E) Expression of *Csf1r* in *Usp18*^{fl/fl} and *Usp18*^{Δ/Δ} mice.









Figure S3, Related to Figure 3. Gene expression and pathway enrichment analysis on macrophage populations


(A) Heatmap of top 5 differentially expressed genes in each cluster.

(B) Pathway enrichment analysis of macrophage clusters by GSEA. The colored pathways indicate relevance to the annotated function of the cluster.

(C) UMAP plots of sub-clustering analysis of cluster 7.


A

Tumor: myeloid cell gating




B

Tumor: lymphoid cell gating




C

Tumor



D

Tumor



TDLN




Figure S4, Related to Figure 4. Flow cytometry analysis of immune cells in tumor and tumor-draining lymph node

(A, B) Gating strategy for subsets of immune cells by flow cytometry; myeloid subsets (A) and lymphoid subsets (B). Samples from tumor are shown.

(C) Percentages of myeloid subsets in tumor.

(D) Percentage of lymphoid subsets in tumor and tumor-draining lymph node (TDLN).

Usp18^{ff} (n = 11), *Usp18^{ΔΔ}* (n = 13). Mean ± S.E.M., two-tailed unpaired *t*-test, *, $p < 0.05$, **, $p < 0.01$